Héctor Olvera

Dr. Héctor Olvera

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EOElizabeth Olivares-Martínez
Elizabeth Olivares-Martínez
DHDiego Francisco Hernández-Ramírez
Diego Francisco Hernández-Ramírez
CNCarlos Alberto Núñez-Álvarez
Carlos Alberto Núñez-Álvarez
DMDAVID EDUARDO MEZA-SANCHEZ
DAVID EDUARDO MEZA-SANCHEZ
MCMónica Chapa
Mónica Chapa
JFJanette Furuzawa-Carballeda
Janette Furuzawa-Carballeda
The intramuscular administration of polymerized type I collagen (PTIC) for adult symptomatic COVID-19 outpatients downregulated hyperinflammation and improved symptoms. We inferred that LAIR1 is a potential receptor for PTIC. Thus, a binding assay and surface plasmon resonance binding assay were performed to estimate the affinity of the interaction between LAIR1 and PTIC. M1 macrophages derived from THP-1 cells were cultured with 2–10% PTIC for 24 h. Lysates from PTIC-treated THP-1 cells, macrophage-like cells (MLCs), M1, M1 + IFN-γ, and M1 + LPS were analyzed by Western blot for NF-κB (p65), p38, STAT1, and pSTAT1 (tyrosine701). Serum cytokine levels and monocyte LAIR1 expressions (Mo1 and Mo2) were analyzed by luminometry and flow cytometry in symptomatic COVID-19 outpatients on PTIC treatment. PTIC-bound LAIR1 had a similar affinity to collagen in M1 macrophages. It downregulated pSTAT1 in IFN-γ-induced M1. COVID-19 patients under PTIC treatment showed a significant decrease in Mo1 percentages and cytokines (IP-10/MIF/eotaxin/IL-8/IL-1RA/M-CSF) associated with STAT1 and an increase in the Mo2 subset. The inflammatory mediators and Mo1 downregulation were related to better oxygen saturation and decreased dyspnea, chest pain, cough, and chronic fatigue syndrome in the acute and long-term phase of infection. PTIC is an agonist of LAIR1 and downregulates STAT-1 phosphorylation. PTIC could be relevant for treating STAT1-mediated inflammatory diseases, including COVID-19 and long COVID.

30 January 2025 in Case Reports in Anesthesiology
Verified
Journal Article
Open access
RGRicardo Eli Guido Guerra
Ricardo Eli Guido Guerra
FMFrancina Valezka Bolaños Morales
Francina Valezka Bolaños Morales
OGOscar Francisco Silva Gómez
Oscar Francisco Silva Gómez
HOHéctor Olvera
Héctor Olvera
SBSarahí Ibáñez Barzalobre
Sarahí Ibáñez Barzalobre
DGDiego Gonzalez-Rivas
Diego Gonzalez-Rivas
Background: Tracheal resection and reconstruction for airway tumors are traditionally performed using general anesthesia, tracheal intubation, and thoracotomy. Modern techniques, such as tubeless tracheal surgery and robotic uniportal approaches, offer several advantages including better surgical conditions, reduced postoperative complications, and faster recovery. Case Report: A 42‐year‐old woman with a tracheal neuroendocrine tumor underwent nonintubated uniportal robotically assisted tracheal resection and reconstruction. Thoracic epidural anesthesia, airway topicalization, and intravenous anesthesia with laryngeal mask airway allowed the procedure to be performed under nonintubated spontaneous ventilation, through a single 3‐cm incision. Postoperative recovery was uneventful, with the patient experiencing minimal pain and no nausea or vomiting. Conclusions: Nonintubated uniportal robotically assisted tracheal resection and reconstruction is a feasible, less invasive technique that offers significant benefits in terms of recovery and patient comfort when performed by experienced surgeons.

11 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
EOElizabeth Olivares-Martínez
Elizabeth Olivares-Martínez
DHDiego Francisco Hernández-Ramírez
Diego Francisco Hernández-Ramírez
CNCarlos Alberto Núñez-Álvarez
Carlos Alberto Núñez-Álvarez
DMDAVID EDUARDO MEZA-SANCHEZ
DAVID EDUARDO MEZA-SANCHEZ
MCMónica Chapa
Mónica Chapa
JFJanette Furuzawa-Carballeda
Janette Furuzawa-Carballeda
The intramuscular administration of polymerized type I collagen (PTIC) for adult symptomatic COVID-19 outpatient downregulated hyperinflammation and improved symptoms. We inferred that LAIR-1 is a potential receptor for PTIC. Thus, binding assay and surface plasmon resonance binding assay were performed to estimate the affinity of the interaction between LAIR-1 and PTIC. M1-macrophage derived from THP-1 cells were cultured with 2-10% PTIC for 24 h. Lysates from PTIC-treated THP-1 cells, macrophages-like cells (MLCs), M1, M1+IFN-γ, and M1+LPS were analyzed by western blot for NF-κB(p65), p38, STAT-1, and pSTAT-1 (tyrosine701). Serum cytokine levels and monocyte LAIR-1 expression (Mo1 and Mo2) were analyzed by luminometry and flow cytometry in symptomatic COVID-19 outpatients on PTIC treatment. PTIC-bound LAIR-1 with a similar affinity to collagen in M1-macrophages. It downregulated pSTAT-1 in IFN-γ-induced M1. COVID-19 patients under PTIC treatment significantly decreased Mo1 percentage and cytokines (IP-10/MIF/eotaxin/IL-8/IL-1RA/M-CSF) associated with STAT-1 and increased Mo2 subset. The inflammatory mediators and Mo1 downregulation were related to better oxygen saturation and decreased dyspnea, chest pain, cough, and chronic fatigue syndrome in the acute and long-term phase of infection. PTIC is an agonist of LAIR-1 and downregulates STAT-1 phosphorylation. PTIC could be relevant for treating STAT-1-mediated inflammatory diseases, including COVID-19 and long-COVID.

17 May 2021 in medRxiv
Verified
Preprint
Open access
PDF file
SMSilvia Méndez-Flores
Silvia Méndez-Flores
APAngel Alexis Priego-Ranero
Angel Alexis Priego-Ranero
DLDaniel Azamar Llamas
Daniel Azamar Llamas
HOHéctor Olvera
Héctor Olvera
KRKenia Rivas
Kenia Rivas
JFJanette Furuzawa-Carballeda
Janette Furuzawa-Carballeda
BACKGROUND: Currently, therapeutic options for ambulatory COVID-19 patients are limited. OBJECTIVE: To evaluate the safety, efficacy and effect of the intramuscular administration of polymerized type I collagen (PTIC) on hyperinflammation, oxygen saturation and symptom improvement in adult outpatients with symptomatic COVID-19. DESIGN: Double-blind, randomised, placebo-controlled clinical trial of PTIC vs placebo. SETTING: Single Third-level hospital in Mexico City (Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán) PARTICIPANTS: Eighty-nine adult participants with a confirmed COVID-19 diagnosis and symptom onset within the 7 days preceding recruitment were included from August 31, 2020 to November 7, 2020 and followed for 12 weeks. Final date of follow-up was February 4, 2021. INTERVENTIONS: Patients were randomly assigned to receive either 1.5 ml of PTIC intramuscularly every 12 h for 3 days and then every 24 h for 4 days (n=45), or matching placebo (n=44). MAIN OUTCOMES AND MEASURES: The primary outcome was a mean reduction of at least 50% in the level of IP-10 compared to baseline. The secondary outcomes were mean oxygen saturation ≥92% while breathing ambient air and duration of symptoms. RESULTS: Of 89 patients who were randomised, 87 (97.8%) were included in an intention-to-treat analysis; 37 (41.6%) were male and mean age was 48.5±14.0 years. The IP-10 levels decreased 75% in the PTIC group and 40% in the placebo group vs baseline. The comparison between treatment vs placebo was also statistically significant ( P= 0.0047). The IL-8 (44%, P= 0.045), M-CSF (25%, P= 0.041) and IL-1Ra (36%, P= 0.05) levels were also decreased in the PTIC group vs baseline. Mean oxygen saturation ≥92% was achieved by 40/44 (90%), 41/42 (98%) and 40/40 (100%) of participants that received PTIC at 8, 15 and 97 days of follow-up vs 29/43 (67%), 31/39 (80%) and 33/37 (89%) of patients treated with placebo ( P =0.001). The unadjusted accelerated failure time model showed that patients treated with PTIC achieved the primary outcome 2.70-fold faster ( P <0.0001) than placebo. In terms of risk, the group of patients treated with PTIC had a 63% lower risk of having a mean oxygen saturation <92% vs placebo ( P <0.0001). Symptom duration in patients treated with PTIC was reduced by 6.1±3.2 days vs placebo. No differences in adverse effects were observed between the groups at 8, 15 and 97 days of follow-up. CONCLUSIONS: In this study, treatment with PTIC down-regulated IP-10, IL-8, M-CSF and IL-Ra levels, which could explain the PTIC effect on the higher proportion of patients with mean oxygen saturation readings ≥92% and a shorter duration of symptoms as compared to patients treated with placebo. Although results are encouraging, larger randomised trials are needed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04517162

23 August 2026 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
PLPaola Renata Lamoyi‐Domínguez
Paola Renata Lamoyi‐Domínguez
NRNADIA RODRIGUEZ
NADIA RODRIGUEZ
VAValeria Alanis‐Toledo
Valeria Alanis‐Toledo
DCDiego Emiliano Chávez‐Fernández
Diego Emiliano Chávez‐Fernández
HOHéctor Olvera
Héctor Olvera
IOIván Armando Osuna‐Padilla
Iván Armando Osuna‐Padilla

1 July 2023 in medRxiv
Verified
Preprint
Open access
PDF file
EOElizabeth Olivares-Martínez
Elizabeth Olivares-Martínez
DHDiego Francisco Hernández-Ramírez
Diego Francisco Hernández-Ramírez
CNCarlos Alberto Núñez-Álvarez
Carlos Alberto Núñez-Álvarez
MCMónica Chapa-Ibarguengoitia
Mónica Chapa-Ibarguengoitia
SMSilvia Méndez-Flores
Silvia Méndez-Flores
JFJanette Furuzawa-Carballeda
Janette Furuzawa-Carballeda
Background: The polymerized type I collagen (PTIC) is a γ-irradiated mixture of pepsinized porcine type I collagen and polyvinylpyrrolidone (PVP). It has immunomodulatory properties. However, the receptor and signaling pathway through which it exerts its therapeutic effects has not yet been identified. Aim: To evaluate LAIR-1 as a potential receptor for PTIC and the signaling pathway evoked by ligand-receptor binding. Methods: LAIR-1 binding assay was performed by incubating various concentrations of recombinant human LAIR-1 with native type I collagen or PTIC. Macrophages M1- derived from THP-1 cells were cultured with 2-10% PTIC for 24 h. Cell lysates from THP- 1, monocytes-like cells (MLCs), M1, M1+IFN-γ, M1+LPS, and 2 or 10% PTIC treated M1 were analyzed by western blot for the transcription factors NF-κB (p65), p38, STAT-1, and pSTAT-1. Cytokines, Th1 cells, and M1/M2 macrophages were analyzed by luminometry and flow cytometry from blood samples of symptomatic COVID-19 outpatients on treatment with intramuscular administration of PTIC. Results: PTIC binds LAIR-1 with a similar affinity to native collagen. This binding decreases STAT-1 signaling IFN-γ-induced and IL-1β expression in M1 macrophages by down-regulating STAT-1 phosphorylation. Moreover, intramuscular PTIC treatment of symptomatic COVID-19 outpatients decreased at statistically significant levels the percentage of M1 macrophages and cytokines (IP-10, MIF, eotaxin, IL-8, IL-1RA, and M- CSF) associated with STAT-1 transcription factor and increased M2 macrophages and Th1 cells. The downregulation of inflammatory mediators was related to better oxygen saturation and decreased dyspnea, chest pain, cough, and chronic fatigue syndrome in the acute phase of infection and the long term. Conclusion: PTIC is an agonist of LAIR-1 and down-regulates STAT-1 phosphorylation. PTIC could be relevant for treating STAT-1-mediated inflammatory diseases, including COVID-19 and long COVID